SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 737.00+4.8%Nov 20 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
The Ox
From: Biotech Jim12/13/2017 2:52:39 PM
1 Recommendation  Read Replies (1) of 3559
 
Looks like the market is buying up on the Sanofi Analyst Day presentation.


Immunology and Inflammation: Dupixent® (dupilumab) and IL-33 antibody


? represents bullet points

? A supplemental Biologics License Application (sBLA) for dupilumab in persistent, uncontrolled asthma is expected to be submitted in the fourth quarter of 2017.

? In 2018, a Dupixent® (dupilumab) sBLA submission is planned for atopic dermatitis in adolescents ages 12 to 17, and in 2019, a second sBLA is planned for children ages 6 to 12.

? In 2019, an sBLA is planned for dupilumab in adults with nasal polyposis.

? Pivotal Phase 3 studies are planned for 2018 evaluating the use of dupilumab in chronic obstructive pulmonary disease (COPD), a condition for which there are no approved biologic therapies.

? A pivotal Phase 3 study is planned for 2018 evaluating the use of dupilumab in eosinophilic esophagitis (EoE), a condition for which there are no approved therapies in the U.S.

? Phase 2 studies investigating the use of dupilumab as an adjunctive therapy to immunotherapies for the treatment of peanut and grass allergy are planned for 2018.

? Dupilumab studies are planned for 2018 to evaluate patients with comorbid allergic inflammatory conditions.

? REGN3500, an antibody to IL-33, is currently being investigated in Phase 1b studies in adult patients with moderate asthma and mild allergic asthma both as monotherapy and in combination with dupilumab.

? In 2018, the companies plan to initiate Phase 2 proof-of-concept studies for REGN3500 in asthma and COPD, and a Phase 2b study in atopic dermatitis.

And much more at: files.shareholder.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News